Alkermes plc (ALKS) Tops Q4 EPS by 3c; Announces Positive Top-Line Data from ARISTADA PK Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2015 and Provides Financial Expectations for 2016
February 25, 2016 7:01 AM ESTRevenues of $628 Million, GAAP Loss Per Share of $1.52 and Non-GAAP Diluted Loss Per Share of $0.36 Reported for Calendar 2015
VIVITROL® Net Sales Grew by 53% Year-Over-Year to $144.4 Million
2016 Revenues Expected to Grow by 15% to 20%, Driven by Continuing
Growth of VIVITROL and Launch of ARISTADA® Into
Rapidly Growing Long-Acting
Antipsychotic Market
Pivotal Clinical Programs Underway for Late-Stage CNS Pipeline for Schizophrenia, Multiple Sclerosis and Major Depressive Disorder
DUBLIN--(BUSINESS WIRE)--... More
Alkermes Announces Positive Topline Results From Clinical Study of Two-Month Dosing Option of ARISTADA® for Treatment of Schizophrenia
February 25, 2016 7:00 AM ESTCompany to File Supplemental New Drug Application With FDA in Second Half of 2016
Potential New Offering Would Expand Range of ARISTADA Doses to Three Interval Options: Once Monthly, Once Every Six Weeks and Once Every Two Months
DUBLIN, Ireland--(BUSINESS WIRE)-- Alkermes plc (NASDAQ: ALKS) today announced positive topline data from a randomized, open-label, pharmacokinetic (PK) study evaluating a two-month... More
